Please Wait.....
Report
Global Parkinson's Disease Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 115 Pages I Mordor Intelligence
Global Parkinson's Disease Drugs Market Analysis
The Parkinson disease market is valued at USD 5.76 billion in 2025 and is projected to reach USD 6.87 billion by 2030, registering a 3.58% CAGR. Growth reflects an expanding patient pool and steady uptake of both symptomatic and disease-modifying options. Carbidopa-levodopa combinations retain commercial primacy, yet adenosine A2A antagonists advance fastest as clinicians seek complementary non-dopaminergic relief. Continuous infusion devices win clinical favor for reducing motor fluctuations, while digital pharmacies widen access to therapy. North America preserves revenue leadership, whereas Asia Pacific posts the quickest expansion as aging trends accelerate and reimbursement frameworks broaden.
Global Parkinson's Disease Drugs Market Trends and Insights
Rising Geriatric Population & Rising Disease Burden
The global Parkinson patient base is projected to reach 25.2 million by 2050, more than doubling its 2021 level as longevity increases worldwide. East Asia shoulders the largest absolute case growth, while western Sub-Saharan Africa records the steepest percentage rise, steering investment toward region-tailored care models . Annual U.S. economic burden already tops USD 52 billion, prompting payer emphasis on early intervention to curb long-term disability costs.
Growing Awareness & Early Diagnosis Initiatives
AI-enabled blood assays can predict disease onset seven years before overt symptoms, allowing enrollment into neuroprotective trials earlier than ever. Complementary smartwatch analytics on 100,000 participants validated motion-pattern biomarkers that flag prodromal cases. Thailand's nationwide digital screening illustrates how low-cost tools enlarge detection in middle-income settings. Earlier diagnosis increases the addressable base for pipeline disease-modifying products.
Adverse Events Associated With Current Therapeutics
Chronic levodopa exposure produces motor complications; benserazide regimens show odds ratios of 170.74 for on-off phenomena, markedly higher than carbidopa's 67.5. Dopamine agonists carry impulse-control risks, and deep-brain stimulation involves surgical morbidity, limiting uptake outside high-resource centers.
Other drivers and restraints analyzed in the detailed report include:
Expanding Reimbursement & Insurance Coverage / Increasing R&D Investment & Continuous Drug Approvals / Adoption of Long-Acting Continuous Infusion Formulations / AI-Driven Drug-Repurposing Pipelines Targeting ?-Synuclein / High Treatment & R&D Costs /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
The Carbidopa-levodopa segment led the Parkinson disease market with a 35.43% share in 2024, supported by decades of clinical familiarity. Adenosine A2A antagonists, though niche, are the quickest-growing class at 4.25% CAGR. Selective D1/D5 partial agonist tavapadon achieved significant MDS-UPDRS gains in Phase 3, reinforcing appetite for mechanisms that preserve dopaminergic signaling while reducing dyskinesia risk.
Pipeline diversification tempers reliance on dopamine modulation. AI-derived ?-synuclein inhibitors and GDNF gene-therapy vectors illustrate a pivot toward disease modification. As these reach commercial stages, the Parkinson disease market size for non-dopaminergic categories is expected to widen, enhancing therapeutic choice and competitive differentiation.
The Report Covers Parkinson's Disease Therapeutics Market and It is Segmented by Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B Inhibitors, Carbidopa-Levodopa, and More), Route of Administration (Oral, Transmucosal, and More), by Distribution Channel (Hospital Pharmacies, Online Pharmacies, and More), and Geography. The Market Provides the Value (in USD Million) for the Above Segments.
Geography Analysis
North America contributed 44.35% of global value in 2024, leveraging well-funded health systems, comprehensive insurance, and dense movement-disorder specialist networks. Federal initiatives such as the National Plan to End Parkinson's Act earmark additional research financing, sustaining innovation momentum. Yet rural communities still face longer diagnostic delays due to limited neurologist access.
Asia Pacific ranks as the fastest-growing region at 5.28% CAGR to 2030. China's case load has soared since 1990, and clinician awareness of non-motor symptoms is improving, although rural treatment gaps persist. Japan's super-aged demographics spur demand for advanced devices, while India's expanding middle class boosts volume, albeit constrained by uneven specialist distribution. Regulatory harmonization across ASEAN members trims approval timelines, favoring multinational launches.
Europe enjoys consistent uptake backed by universal insurance, but individual-state reimbursement decisions create variability. Brexit-related customs changes caused occasional levodopa shortages in the United Kingdom, prompting calls for resilient supply strategies. Germany's 2025 guideline update emphasizes early interdisciplinary management, reinforcing stable demand across drug classes. Latin America and Middle East & Africa display emerging opportunities parallel to rising life expectancy and improving neurologic care infrastructure.
List of Companies Covered in this Report:
Abbvie / Amneal Pharmaceuticals / Viatris / Boehringer Ingelheim Intl. GmbH / GlaxoSmithKline / Teva Pharmaceutical Industries / Pfizer / Novartis / Roche / ABL bio / KISSEI PHARMACEUTICAL / AstraZeneca / Prevail Therapeutics / Newron Pharmaceuticals S.p.A. / Kyowa Kirin / ACADIA Pharmaceuticals Inc. / UCB / Sunovion Pharmaceuticals / Neurocrine Biosciences / Lundbeck A/S / Voyager Therapeutics, Inc. / Supernus Pharmaceuticals /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population & Rising Disease Burden
4.2.2 Growing Awareness & Early Diagnosis Initiatives
4.2.3 Expanding Reimbursement & Insurance Coverage
4.2.4 Increasing R&D Investment & Continuous Drug Approvals
4.2.5 Adoption Of Long-Acting Continuous Infusion Formulations
4.2.6 Ai-Driven Drug-Repurposing Pipelines Targeting ?-Synuclein
4.3 Market Restraints
4.3.1 Adverse Events Associated With Current Therapeutics
4.3.2 High Treatment & R&D Costs
4.3.3 Supply-Chain Constraints For Levodopa Apis
4.3.4 Regulatory Uncertainty Around Disease-Modifying Claims
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers/Consumers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitute Products
4.7.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD million)
5.1 By Mechanism of Action
5.1.1 Dopamine Agonists
5.1.2 Anticholinergics
5.1.3 MAO-B Inhibitors
5.1.4 Amantadine
5.1.5 Carbidopa-levodopa
5.1.6 Adenosine A2A Antagonists
5.1.7 Other Mechanisms of Action
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Transdermal
5.2.3 Subcutaneous
5.2.4 Infusion
5.2.5 Intranasal
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 AbbVie Inc.
6.3.2 Amneal Pharmaceuticals LLC
6.3.3 Viatris
6.3.4 Boehringer Ingelheim Intl. GmbH
6.3.5 GSK plc
6.3.6 Teva Pharmaceutical Industries Ltd
6.3.7 Pfizer Inc.
6.3.8 Novartis AG
6.3.9 F. Hoffmann-La Roche Ltd
6.3.10 ABL bio
6.3.11 Kissei Pharmaceutical Co., Ltd.
6.3.12 AstraZeneca
6.3.13 Prevail Therapeutics
6.3.14 Newron Pharmaceuticals S.p.A.
6.3.15 Kyowa Kirin Co., Ltd.
6.3.16 ACADIA Pharmaceuticals Inc.
6.3.17 UCB S.A.
6.3.18 Sunovion Pharmaceuticals Inc.
6.3.19 Neurocrine Biosciences, Inc.
6.3.20 Lundbeck A/S
6.3.21 Voyager Therapeutics, Inc.
6.3.22 Supernus Pharmaceuticals, Inc.
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security